XIPERE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Xipere, and when can generic versions of Xipere launch?

Xipere is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-one patent family members in eighteen countries.

The generic ingredient in XIPERE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xipere

A generic version of XIPERE was approved as triamcinolone acetonide by TARO on October 1^st, 1986.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for XIPERE?
What are the global sales for XIPERE?
What is Average Wholesale Price for XIPERE?

Summary for XIPERE

International Patents:	81
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	83
Patent Applications:	4,319
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XIPERE
What excipients (inactive ingredients) are in XIPERE?	XIPERE excipients list
DailyMed Link:	XIPERE at DailyMed

Drug patent expirations by year for XIPERE

Pharmacology for XIPERE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for XIPERE

XIPERE is protected by three US patents and one FDA Regulatory Exclusivity.

Patents protecting XIPERE

Methods and devices for drug delivery to ocular tissue using microneedle
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

Methods and devices for the treatment of ocular diseases in human subjects
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

Apparatus and methods for ocular injection
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting XIPERE

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for XIPERE

See the table below for patents covering XIPERE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	6379183		⤷ Sign Up
World Intellectual Property Organization (WIPO)	2014179698		⤷ Sign Up
Japan	2016520383	眼球注射の装置および方法	⤷ Sign Up
South Korea	20210032571	인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 (METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration